Meta Pixel Code
(818) 322-0122 BOOK NOW

Comprehensive Guide to Subcutaneous Self-Injection of Tirzepatide

This guide provides a step-by-step, evidence-based overview of how to safely and effectively self-administer tirzepatide using a pre-filled injection pen. Readers will learn about proper medication handling and storage, preparation of injection supplies, site selection and cleaning, the three-step injection process, and essential post-injection care.

By following these instructions, patients can ensure correct dosing, minimize complications, and maintain best practices for safe disposal and continued treatment success.

Detailed Image Of Tirzepatide Vial, Syringe And Tirzepatide Molecule Organized Nicely

What Is Tirzepatide?

Tirzepatide is a once-weekly injectable medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes (brand name: Mounjaro, FDA approval May 2022; NDA 215866) and chronic weight management in adults with obesity or overweight (brand name: Zepbound, FDA approval November 2023; NDA 215866/S-002).

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It works by enhancing insulin secretion, suppressing glucagon, and reducing appetite.

References: FDA Mounjaro Approval, FDA Zepbound Approval

Indications and Contraindications

Approved Uses

  1. Type 2 diabetes mellitus (as an adjunct to diet and exercise)
  2. Chronic weight management in adults with BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity

Contraindications

  1. Personal or family history of medullary thyroid carcinoma (MTC)
  2. Multiple endocrine neoplasia syndrome type 2 (MEN 2)
  3. Hypersensitivity to tirzepatide or any component of the formulation

Note: Tirzepatide is not indicated for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

Preparation for Self-Injection

Supplies Needed

  1. Tirzepatide single-use prefilled pen (Mounjaro or Zepbound)
  2. Alcohol swab
  3. Sterile cotton ball or gauze
  4. Sharps disposal container

Supplies For A Tirzepatide Injection: A Single-Dose Pen, Alcohol Swab, Cotton Ball, And Sharps Container

Storage and Handling

  1. Store tirzepatide pens in the refrigerator (36°F to 46°F/2°C to 8°C).
  2. Pens may be kept at room temperature (up to 86°F/30°C) for up to 21 days.
  3. Do not freeze. Discard if frozen.
  4. Protect from light. Keep in the original carton until use.

Step-by-Step Guide to Subcutaneous Self-Injection

1. Wash Hands

  • Wash hands thoroughly with soap and water to minimize infection risk.

2. Inspect the Pen

  • Check the expiration date.
  • Ensure the solution is clear and colorless; do not use if cloudy or contains particles.

3. Choose an Injection Site

  • Recommended sites: abdomen (at least 2 inches from the navel), front of thighs, or upper outer arm.
  • Rotate injection sites weekly to reduce risk of lipodystrophy or irritation.
  • Avoid areas with scars, bruises, or broken skin.

4. Clean the Skin

  • Wipe the selected site with an alcohol swab and allow to dry.

5. Prepare the Pen

  • Remove the pen cap.
  • Follow manufacturer instructions to unlock and prime the pen if required (most tirzepatide pens are pre-set and do not require priming).

6. Inject the Medication

  • Pinch the skin gently to create a fold.
  • Place the pen at a 90-degree angle to the skin.
  • Press and hold the injection button until the dose counter shows “0” and you hear a click (typically 10 seconds).
  • Remove the pen and release the skin fold.

7. Dispose of the Pen

  • Place the used pen in a FDA-cleared sharps disposal container.
  • Do not reuse the pen or needle.

8. Monitor for Side Effects

  • Mild redness or swelling at the injection site is common and usually resolves quickly.
  • Contact your healthcare provider if you experience persistent pain, swelling, or signs of infection.

Safety Considerations

Common Side Effects

  • Nausea, vomiting, diarrhea, decreased appetite, constipation, and abdominal pain
  • Injection site reactions (redness, itching, swelling)
  • Hypoglycemia (especially if used with insulin or sulfonylureas)

Serious Risks

  • Pancreatitis: Seek immediate medical attention for severe abdominal pain.
  • Hypersensitivity reactions: Discontinue and seek care if symptoms occur.
  • Risk of thyroid C-cell tumors: Contraindicated in patients with relevant history.

Individual results may vary. Always consult your healthcare provider for personalized guidance.

Missed Dose and Troubleshooting

  • If a dose is missed, administer as soon as possible within 4 days. If more than 4 days have passed, skip the missed dose and resume the regular schedule.
  • Do not take two doses within 3 days of each other.
  • If you have difficulty using the pen or are unsure about the injection, contact your healthcare provider or pharmacist for assistance.

Disposal of Used Pens

  • Dispose of used pens in a sharps disposal container.
  • Do not throw pens in household trash.
  • Follow local regulations for medication and sharps disposal.

When to Contact Your Healthcare Provider

  • Signs of allergic reaction (rash, swelling, difficulty breathing)
  • Persistent vomiting or diarrhea
  • Severe abdominal pain
  • Signs of infection at the injection site
  • Unexplained lumps or swelling in the neck (possible thyroid issues)

Frequently Asked Questions

What is tirzepatide used for?

Tirzepatide is FDA-approved for type 2 diabetes management (Mounjaro) and chronic weight management (Zepbound) in adults with obesity or overweight.

How often do I inject tirzepatide?

Tirzepatide is administered once weekly, on the same day each week.

Can I inject tirzepatide in the same spot every week?

No. Rotate injection sites to reduce the risk of skin irritation or lipodystrophy.

What should I do if I miss a dose?

Inject as soon as possible within 4 days. If more than 4 days have passed, skip the missed dose and continue with your next scheduled dose.

How do I store tirzepatide pens?

Store in the refrigerator. Pens may be kept at room temperature for up to 21 days. Do not freeze.

What are the most common side effects?

Nausea, vomiting, diarrhea, decreased appetite, and mild injection site reactions.

Can I use tirzepatide if I have a history of thyroid cancer?

No. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.

Is it safe to self-inject tirzepatide?

Yes, when following the manufacturer’s instructions and under the guidance of a healthcare provider.

What should I do with used pens?

Dispose of them in a sharps disposal container according to local regulations.

Should I contact my provider if I have side effects?

Yes. Contact your healthcare provider for any persistent, severe, or concerning symptoms.

References

  1. Eli Lilly and Company. (2023). Instructions for Use, MOUNJARO® (tirzepatide) injection. U.S. Food and Drug Administration. Retrieved September 12, 2025, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215866s004lbl.pdf
  2. Eli Lilly and Company. (2023). Instructions for Use, ZEPBOUND™ (tirzepatide) injection. U.S. Food and Drug Administration. Retrieved September 12, 2025, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
  3. Mounjaro® Official Patient Website. How to Use the Mounjaro Pen. Eli Lilly and Company. Retrieved September 12, 2025, from https://www.mounjaro.lilly.com/how-to-use-mounjaro
  4. U.S. Food and Drug Administration (FDA). (2021). Safely Using Sharps (Needles and Syringes) at Home, at Work, and on the Go. Retrieved September 12, 2025, from https://www.fda.gov/medical-devices/consumer-products/safely-using-sharps-needles-and-syringes-home-work-and-travel